This analysis examines the current position and future outlook for Lundbeck in the ethical pharmaceutical sector. The profile encompasses global and US strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information

• Benchmark Lundbeck's performance against key rivals in the ethical pharmaceutical sector
• Assess the company's successful strategy to preserve sales after the global genericization of Cipramil/Celexa
• Understand why the success of the company's licensing strategy in obtaining product marketing rights will determine its ability to drive growth